The US Food and Drug Administration (FDA) has approved St Jude Medical's Ilumien system, a combined technology integrating optical coherence tomography (OCT) and fractional flow reserve (FFR) technologies on a single platform.
The Ilumien system features the company’s wireless interventional tool – PressureWireAeris – to measure FFR and assess the severity of blood flow blockages in the coronary arteries.
It also features the company’s C7-XR OCT diagnostic imaging technology which aids physicians to see and measure important vessel characteristics.
The combined technologies also aid physicians with precise measurements of lesion dimensions, as well as vessel size and structure.
Denver Health Medical Center cardiac catheterization laboratory director Joel Garcia said the system offers physicians a simplified, streamlined option for the diagnosis and treatment of patients with culprit lesions that are in need of treatment strategies with advanced therapy guidance.